The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

Drug developer GSK is vacating its 635,000-square-foot life sciences lab in Rockville, Maryland, where it was the sole tenant ...

Gilead Sciences, Inc. GILD reported better-than-expected fourth-quarter results and provided an upbeat guidance for 2025.

GSK is also running a third phase 3 trial of depemokimab, called NIMBLE, that is exploring the use of the drug in patients switched from Nucala or Fasenra and is also studying it in other Nucala ...

The U.S. Food and Drug Administration said on Tuesday it has approved SpringWorks Therapeutics' drug to treat a type of rare ...